DI
Therapeutic Areas
Pliant Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bexotegrast (PLN-74809) | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2b/3 |
| PLN-101095 | Muscular Dystrophies | Phase 1 |
| PLN-1474 | Non-alcoholic Steatohepatitis (NASH) / Liver Fibrosis | Preclinical |
Leadership Team at Pliant Therapeutics
BC
Bernard Coulie, M.D., Ph.D.
President and Chief Executive Officer
KC
Keith Cummings, M.D., MBA
Chief Financial Officer
MK
Minnie Kuo
Chief Operating Officer
LC
Lily Cheung
Chief Human Resources Officer
TM
Tim Machajewski, Ph.D.
Senior Vice President, Head of Research
DP
Daniel Park
Senior Vice President, Development Operations
CK
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
HH
Hoyoung Huh, M.D., Ph.D.
Chairman of the Board
SB
Suzanne Bruhn, Ph.D.
Board Member
DE
David E. I. Pyott
Board Member